Monitor upcoming financial filings for disclosure of the exact number of RSUs granted and associated compensation expense. The move signals stabilized cash flow post-financing, but the dilutive impact of new equity grants could pressure shares if revenue growth doesn't follow.
LGVN drugs
LGVN drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 13 $1.12entry
- T+1 · 7mo ago 0.00%α −1.21% · $1.12
- T+5 · 7mo ago −7.14%α −10.44% · $1.04
- T+20 · 6mo ago −25.18%α −32.91% · $0.8380
- T+60 · 4mo ago −42.59%α −51.51% · $0.6430
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Longeveron Inc. restored executive and board compensation after a temporary reduction and approved restricted stock unit (RSU) grants totaling 250,000 for each executive (500,000 for the CEO) as a reward for securing financing. The RSUs will vest quarterly over three years starting July 1, 2026.
Key Facts
- Temporary executive and board compensation reductions (25%-50%) were reversed after successful financing closed on March 12, 2026
- Each executive (except Executive Chairman) will receive 250,000 RSUs; the CEO will receive 500,000 RSUs
- RSU grants will be issued on May 1, 2026, and vest quarterly over three years starting July 1, 2026
- Compensation adjustments were made due to prior cash runway concerns, now resolved by financing
Financial Impact
Restoration of prior compensation levels and issuance of up to 1.25 million RSUs (exact value depends on stock price at grant date)
Risk Factors
- Potential share dilution from issuance of up to 1.25 million RSUs
- No assurance of sustained financial stability if future capital raises are needed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-042565 |
| Document: 0001213900-26-042565-index-headers.html | 0001213900-26-042565 |
| Document: 0001213900-26-042565-index.html | 0001213900-26-042565 |
| Document: 0001213900-26-042565.txt | 0001213900-26-042565 |
Track record
22 reports on LGVN
4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +44.65% at T+20 after the Sep 16, 2026 report. 7 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $2.53 Now $2.14 +15.42% settles Feb 12
- Nov 13, 20263d ago SC 13G Neutral 4/10 Entry $2.49 Now $2.14 −14.06% settles Feb 11
- Nov 12, 20264d ago 8-K Bearish 7/10 No price data
- Nov 12, 20264d ago Press Release Bearish 6/10 Entry $2.49 Now $2.14 +14.06% settles Feb 11
- Nov 5, 202611d ago SC 13G/A Bearish 5/10 Entry $1.81 Now $2.14 −18.23% settles Feb 4
- Nov 5, 202611d ago 8-K Neutral 2/10 Entry $1.81 Now $2.14 +18.23% settles Feb 4
- Oct 26, 202621d ago 8-K Neutral 5/10 Entry $1.73 Now $2.14 +23.70% settles Jan 25
- Oct 26, 202621d ago Press Release Mixed 6/10 Entry $1.61 Now $2.14 +33.33% settles Jan 22
- Oct 14, 20264w ago 8-K Neutral 3/10 Entry $1.50 Now $2.14 +42.67% settles Jan 12
- Sep 16, 20268w ago Press Release Bearish 7/10 Entry $2.71 Now $2.14 +21.03% settles Dec 11
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers